里昂发表报告指，信达生物在6月28日举行的研发日上提供肿瘤专营权的深入更新。重点在于新一代I/O和ADC平台的建立，特别是PD-1/IL-2 IBI363。该行将公司目标价由55.9港元上调至108.4港元，维持“跑赢大市”评级。里昂上调信达生物2025至2027财年销售额预测各1%、1.3%及3.6%，纯利预测升8.9%、6.8%及13.3%，以反映公司近期的产品线进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.